

ADPS

Next-Level Alzheimer's
Disease Screening



The Alzheimer's Disease Prediction Service (ADPS) is an EIT Health Innovation project with the vision of making brain health measurable and thus actionable.

Current state-of-the-art diagnostic measures of Alzheimer's disease (AD) are invasive (cerebrospinal fluid analysis), expensive (neuroimaging) and time-consuming (neuropsychological assessment) and thus have limited accessibility as frontline screening and diagnostic tools for AD. According to the 2014 Alzheimer report, only 35% of dementia cases are diagnosed early enough.

After a 10-minute iPad-based test, ADPS is able to tell if someone will develop AD within 6 years, with an accuracy of 94%. ADPS will be one of the first validated solutions to enter the EU & US markets as a pre-symptomatic, computational biomarker to predict AD risk for people over 50.

Based on easily collectable digital behavioural markers, the platform measures cognitive outcomes using smartphone sensors. Neurologists are able to screen and monitor healthy, at-risk as well as Mild Cognitive Impairment/AD prodromal patients.

ADPS is currently deployed to neurologists and primary care physicians as a cognitive assessment tool for patients and to global biopharmaceutical companies to assist with the discovery of novel treatments for AD.



The smartphone-based technology will simplify disease progression tracking and allow more precise and personalised prognosis, treatment, and interventions for AD, one of society's greatest challenges. More data will lead to better understanding and will be key to developing powerful new drugs and novel treatments.

Achievements so far

To date, ADPS research has been conducted in longitudinal EU-funded studies with 4500 candidates (2700 AD prodromal) across 22 sites, including the TILDA study in collaboration with Global Brain Health Institute. Research has been published in 12 major journals and 240 independent publications and both Alzheimer's Europe and the US Alzheimer's Association have endorsed ADPS. Altoida, the spin-off company responsible for ADPS, was recognized as a Rice Alliance "10 Most Promising Life Science Companies" at the 2017 Texas Life Science Forum in Houston, USA.

Benefits of EIT Health support

The EIT Health Innovation project team:

- Facilitates the project to further evaluate the accuracy and performance of the ADPS prototype
- Collaborates across borders with experts in research, business and education to build the reputation of ADPS amongst key opinion leaders
- Creates links with payers and public authorities and supports with funding, expertise and access to market allowing commercialisation of ADPS across the European market.



Team



UNIVERSITAT DE
BARCELONA



Institut
D'Investigacions
Biomèdiques
August Pi i Sunyer



Trinity College Dublin
Coláiste na Tríonóide, Baile Átha Cliath
The University of Dublin

Visit the Altoida website: www.altoida.com

For more information about ADPS and other EIT Health success stories, please contact:

Sabine Schumann,
Head of Communications.

t: +49 151 16 36 96 07

e: sabine.schumann@eithealth.eu